Our systems are now restored following recent technical disruption, and we’re working hard to catch up on publishing. We apologise for the inconvenience caused. Find out more

Recommended product

Popular links

Popular links


Principles of Translational Science in Medicine

Principles of Translational Science in Medicine

Principles of Translational Science in Medicine

From Bench to Bedside
Martin Wehling, Ruprecht-Karls-Universität Heidelberg, Germany
Francesco M. Marincola
December 2009
Available
Hardback
9780521888691
$94.00
USD
Hardback

    Despite advancements in the cloning of the total human genome, biomedical innovations at the patient level are becoming rare events. However, translational medicine is a burgeoning science that shows the potential to reverse the trend. This textbook will comprise a state-of-the-art survey of translational medicine, with emphasis on its emerging scientific backbone, its strengths, and its weaknesses. It explores all aspects of preclinical and clinical issues that are relevant to the success of translational pharmaceutical or medical device or diagnostic innovations, including target risk assessment, biomarker evaluation, and predictivity grading for both efficacy and toxicity; early human trial designs that are adequate to guide stop or go decisions on the grounds of biomarker panels; and biostatistical methods to analyze multiple readout situations and quantify risk projections. The book provides guidance to design smart profiling strategies for new approaches aimed at cutting timelines and concentrating on the comparison of quality issues of early developmental processes for pharmaceutical and biotechnology research. By furthering the substantiation of translational medicine, creating awareness about its potential to promote innovations into clinical practice, and examining the terminology surrounding current biotechnologies, this book hopes to create a dialogue about translational science and what this will mean for patient care in the near future.

    • Takes a multidisciplinary approach across borders in science: preclinical/clinical
    • Analyzes complex multilayered processes both focused and standardized to create blueprints

    Product details

    December 2009
    Hardback
    9780521888691
    404 pages
    261 × 181 × 25 mm
    1.03kg
    57 b/w illus. 19 colour illus. 30 tables
    Available

    Table of Contents

    • 1. Introduction and definitions M. Wehling 2. Target identification and validation M. Plebani, M. Zaninotto, G. Lippi, E. Marrer, F. Dieterle, J. Vonderscher, D. Stroncek, P. Jin, E. Wang, J. Ren, F. M. Marincola, J. Kirchheiner, W. Peeters, W. J. M. Derksen, D. P. V. de Kleijn, G. Pasterkamp and M. Grasso 3. Biomarkers M. Wehling, D. Bernardi, M. Plebani, L. Lind, F. Azam, R. Midgley, D. J. Kerr, L. Johansson, A. Meyer-Lindenberg and H. Tost 4. Early clinical trial design F. Azam, R. Midgley, D. J. Kerr and C. Karlsson 5. Pharmaceutical toxicology S. Ernst, S. Boyer and S. Platz 6. Translational science biostatistics G. Ferber and E. Glimm 7. Learning by experience: examples of translational processes in the cardiovascular field M. Wehling.
      Contributors
    • M. Wehling, M. Plebani, M. Zaninotto, G. Lippi, E. Marrer, F. Dieterle, J. Vonderscher, D. Stroncek, P. Jin, E. Wang, J. Ren, F. M. Marincola, J. Kirchheiner, W. Peeters, W. J. M. Derksen, D. P. V. de Kleijn, G. Pasterkamp, M. Grasso, D. Bernardi, L. Lind, F. Azam, R. Midgley, D. J. Kerr, L. Johansson, A. Meyer-Lindenberg, H. Tost, C. Karlsson, S. Ernst, S. Boyer, S. Platz, G. Ferber, E. Glimm

    • Editor
    • Martin Wehling , Ruprecht-Karls-Universität Heidelberg, Germany

      Professor Mark Wehling is an internist, cardiologist, and full professor of clinical pharmacology at the University of Heidelberg, Germany. He has authored more than 200 scientific publications and several books and has been recipient of the Heisenberg Scholarship from Deutsche Forschungsgemeinschaft. After working as Director of Discovery Medicine at AstraZeneca, he returned to his academic position in 2007. In his return to academia, his aim is to further translational medicine by aligning academic and private activities to support biomedical innovation. His main tools are connecting distant players in the translational process; bridging gaps between preclinical and clinical stages; assembling, developing, and profiling biomarkers with particular assessment of their predictive value; and developing smart translational plans to reliably and swiftly promote translatable projects.

    • Francesco M. Marincola